AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A compound of Formula (I) ~~compounds~~:



I

where:

A is ~~CX~~CH; alkanylilidene with 2 to 4 carbon atoms~~, particularly CH_2-CH~~;or alkenylilidene with 2 to 4 carbon atoms~~, particularly CH=C~~;

Ar is phenyl~~monocyclic or bicyclic C_6-C_{10} aryl or heteroaryl, containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur,~~ ~~possibly~~optionally substituted by halogens, NO_2, OH, C_1-C_4 alkyl and alkoxy, said alkyl and alkoxy ~~possibly~~optionally substituted by at least one halogen; ~~monocyclic, bicyclic or tricyclic arylalkyl or heteroarylalkyl containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur, where the alkyl residue contains from 1 to 3 carbon~~

~~atoms, said arylalkyl or heteroarylalkyl possibly substituted by halogens, NO_2, OH, C_1-C_4 alkyl and alkoxy,~~

~~said alkyl and alkoxy possibly substituted by at least one halogen;~~

f is the number 0 or 1;

h is the number 0 or 1;

m is a whole number from 0 to 3;

n is the number 0 or 1 and if n is ~~0~~0, R_1 is absent, and COY is directly bound to benzene~~)~~;

Q and Z, which may be the same or different, are selected from the group consisting of NH, 0, S, NHC(O)O, NHC(O)NH, NHC(O)S, OC(O)NH, S(CO)NH, C(O)NH, and NHC(O);

R is selected from R_2, and OR_2;

R_1 is selected from H, COW, SO_3-, OR_3, =0, CN, and NH_2, ~~NHCO(C_6-C_{10})Ar, where Ar may possibly be substituted by halogens, NO_2, OH, C_1-C_4 alkyl and alkoxy, said alkyl and alkoxy possibly substituted by at least one halogen;~~

R_2 is selected from H, or a straight or branched C_1-C_4 alkyl, ~~possibly~~optionally substituted by at least one halogen;

R_3 is selected from H, straight or branched C_1-C_4 alkyl, ~~possibly~~optionally substituted by at least one halogen, ~~(C_6-C_{10})ArCH_2, where Ar is possibly substituted by halogens, NO_2, OH, C_1-C_4 alkyl and alkoxy, said alkyl and alkoxy possibly substituted by at least one halogen;~~

W is selected from OH, OR_4, and NH_2;

R_4 is straight or branched C_1-C_4 alkyl;

Y is selected from OH, OR_5, and NH_2;

R_5 is straight or branched C_1-C_4 alkyl;

or A, COY and R1 together form a cycle of the type:



their pharmacologically acceptable salts, racemic mixtures, individual enantiomers, geometric isomers or stereoisomers, and tautomers.

2. (Currently Amended) A ~~Compounds~~compound according to claim 1, in which Ar is a heteroaryl, ~~preferably containing nitrogen as the heteroatom,~~ and ~~preferably~~optionally f is 0, m is 1 or 2, Q is oxygen, and R is hydrogen.

3. (Currently Amended) A ~~Compounds~~compound according to claim 1, in which Ar is an aryl, ~~possibly~~optionally substituted by one or more halogen atoms, alkyl, alkoxy or lower haloalkyl, nitro, mono- or di-alkylamine, and preferably f is 0, m is 0, 1 or 2, Q is oxygen or HNC(O)O, and R is hydrogen.

4. (currently Amended) A ~~Compounds~~compound according to claim 1, where R_1 is COW.

5. (Currently Amended) A ~~Compound~~compound ~~according to claim 1,~~ selected from the group consisting of:

~~i. Diethyl 4-[2-(1-indolyl)ethoxy]benzylidenemalonate;~~

~~ii. Diethyl 4-[2-(1-indolyl)ethoxy-benzylmalonate;~~

~~iii. Dimethyl 4-[2-(1-indolyl)ethoxy]benzylidenemalonate;~~

~~iv. Dimethyl 4-[2-(1-indolyl)ethoxy]benzylmalonate;~~

~~v. 4-[2-(1-indolyl)ethoxy]benzylrnalonic acid;~~

~~vi. Methyl (2S)-amino-2-[4-[2-(1-indolyl)ethoxy]phenyl]-acetate;~~

~~vii. Methyl 4-[2-(1-indolyl)ethoxy]benzoate;~~

~~viii. Methyl 3-[4-[2-(1-indolyl)ethoxy]phenyl]propanoate;~~

~~ix. Methyl 2-[4-[2-(1-indolyl)ethoxy]phenyl]acetate;~~

~~x. Methyl 2-sulpho-2-[4-[2-(1-indolyl)ethoxy]phenyl]acetate-sodium-salt;~~

~~xi. Methyl (S)-2-benzoylamino-2-[4-[2-(1-indolyl)ethoxy]-phenyl]-acetate;~~

~~xii. Methyl 2-hydroxy-3-[4-[2-(1-indolyl)ethoxy]phenyl]-propanoate;~~

~~xiii.~~ Dimethyl 4-[2- [4-(dimethylamino)phenyl]ethoxy]benzylmalonate;

~~xiv. Methyl 3-[4-[2-(1-indolyl)ethoxy]phenyl]-2-cyano-propenoate;~~

~~xv. Methyl 3-[4-[2-(1-indolyl)ethoxy]phenyl]-2-cyano-propanoate;~~

~~xvi. Dimethyl 4-[2-(3-indolyl)ethoxy]benzylidenemalonate;~~

~~xvii. Dimethyl 4-[2-(-1-naphthyl)ethoxy]benzylmalonate;~~

~~xviii. Dimethyl 4-[2-(2-pyridyl)ethoxy]benzylmalonate;~~

~~xix.~~ Dimethyl 4-[2-(4-chlorophenyl)ethoxy]benzylmalonate;

~~xx.~~ 5-[4-[2-(4-chlorophenyl)ethoxy]phenylmethylene]-thiazolidine-2 ,4-dione;

~~xxi.~~ 5-[4-[2-(4-chlorophenyl)ethoxy]phenylmethyl]thiazolidine-2,4-dione;

~~xxii.~~ Dimethyl 3-[2-(4-chlorophenyl)ethoxy]benzylmalonate;

~~xxiii.~~ Dimethyl 3-[2-(phenyl)ethoxy]benzylmalonate;

~~xxiv.~~ Dimethyl 3-[N- (4-trifluoromethylbenzyl)carbamoyl]-4-methoxybenzylmalonate;

~~xxv.~~ Dimethyl 4-methoxy-3-[2-(4-chlorophenyl)ethoxy]benzyl-malonate:

~~xxvi.~~ Dimethyl 3-(2-phenylethoxy)-4-methoxy benzylmalonate;

~~xxvii.~~ Dimethyl 4-[2-(4-methoxyphenyl)ethoxy]benzylmalonate;

~~xxviii.~~ Dimethyl 4-[3(4-methoxyphenyl)propyloxy]benzyl-malonate;

~~xxix. Dimethyl 4-[2-(2-naphthyl)ethoxy]benzylmalonate;~~

~~xxx.~~ (2S)-2-benzoylamino-3-[4-[(4-methoxybenzyl)-carbamoyl-]oxypheny]ethyl propanoate;

~~xxxi.~~ Dimethyl 4- [[(4-methoxybenzyl)carbamoyl]oxy]benzyl-malonate;

~~xxxii.~~ Dimethyl 4- [[(4-trifluorotolyl)carbamoyl]oxy]benzyl-malonate;

~~xxxiii.~~ Dimethyl 4-[[(2 ,4-dichlorophenyl)carbamoyl]oxy]benzyl-malonate;

~~xxxiv.~~ Dimethyl 4-[[(4-chlorophenyl)carbamoyl]oxy]benzyl-malonate;

~~xxxv. Dimethyl 4-[2-(pyridinio)ethoxy]benzylmalonate methanesulphonate;~~

~~xxxvi.~~ Dimethyl 4-[[(4-nitrophenyl)carbamoyl]oxy]benzyl-malonate;

~~xxxvii.~~ Dimethyl 3- [[(4-methoxybenzyl)carbamoyl]oxy]benzylmalonate;

~~xxxviii.~~Dimethyl 3-[[(4-butylphenyl)carbamoyl]oxy]benzyl-malonate;

~~xxxix.~~ Dimethyl 4-[[(4-butylphenyl)carbamoyl]oxy]benzyl-malonate;

~~xl.~~ Dimethyl 3-[[(4-chlorophenyl)carbamoyl]oxy]benzyl-malonate;

~~xli.~~ (Z)-2-ethoxy-3-[4-[2-(4-chloro-phenyl)ethoxy]-phenyl] ethyl propenoate;

~~xlii.~~ (E)-2-ethoxy-3-[4-[2-(4-chloro-phenyl)ethoxy]-phenyl]ethyl propenoate;

~~xliii.~~ (R,S)-2-ethoxy-3- [4-[2- (phenyl)ethoxy]phenyl]ethyl propanoate;

~~xliv.~~ (R,S)-2-ethoxy-3-[4-[2-(4-chloro-phenyl)ethoxy]-phenyl-]methyl propanoate;

~~xlv. Dimethyl 4- [2-(2,3-dimethyl-1-indolyl)ethoxy]benzyl-malonate~~

5- [3- [2- (4-chlorophenyl) ethoxy] phenylmethylene] thiazolidine-2,4-dione

5- [3- [2- (4-chlorophenyl) ethoxy] phenylmethyl]-thiazolidine-2. 4-dione

3-[[(4-methoxybenzyl)carbamoyl]oxy] benzylmalonate.

6. (canceled).

7. (currently amended) A ~~Pharmaceutical compositions~~pharmaceutical composition containing at least one compound according to claim 1 in mixtures with pharmaceutically acceptable vehicles ~~and/~~and/~~-~~or excipients.

8. (canceled).

9. (withdrawn/currently amended) ~~Use of the compounds according to claim 1 for the preparation of a medicine~~A method for the ~~prophylaxis and~~ treatment of diabetes~~, particularly type 2,~~ and its complications, Syndrome X, the various forms of insulin resistance and

hyperlipdaemias comprising administering to a subject in need of same an effective amount of a compound of claim 1.

10. (withdrawn/new) The method of claim 9 in which the diabetes is type 2.

11. (new) A compound according to claim 1, in which the heteroatom in the heteroalkyl is nitrogen, f is 0, m is 0, 1 or 2, Q is oxygen or HNC(O)O, and R is hydrogen.

12. (new) A compound of Formula (I):



I

where:

A is CH; alkanylilidene with 2 to 4 carbon atomsor alkenylilidene with 2 to 4 carbon atoms;

Ar is phenyloptionally substituted by halogens, NO_2, OH, C_1-C_4 alkyl and alkoxy, said alkyl and alkoxy optionally substituted by at least one halogen;

f is the number 0 or 1;

h is the number 0 or 1;

m is a whole number from 0 to 3;

n is the number 0 or 1 and if n is 0, R_1 is absent, and COY is directly bound to benzene;

Q and Z, which may be the same or different, are selected from the group consisting of NH, 0, S, NHC(O)O, NHC(O)NH, NHC(O)S, OC(O)NH, S(CO)NH, C(O)NH, and NHC(O);

R is selected from R_2, and OR_2;

R_1 is selected from H, COW, SO_3-, OR_3, =0, CN, and NH_2,

R_2 is selected from a straight or branched C_1-C_4 alkyl, optionally substituted by at least one halogen;

R_3 is selected from H, straight or branched C_1-C_4 alkyl, optionally substituted by at least one halogen,

W is selected from OH, OR_4, and NH_2;

R_4 is straight or branched C_1-C_4 alkyl;

Y is selected from OH, OR_5, and NH_2;

R_5 is straight or branched C_1-C_4 alkyl;

and A, COY and R1 together form a cycle of the type:



their pharmacologically acceptable salts, racemic mixtures, individual enantiomers, geometric isomers or stereoisomers, and tautomers.